Immix Biopharma stockholders elect 8 directors and ratify Crowe LLP as 2025 auditor

Immix Biopharma, Inc.

All 8 director nominees elected with 'for' votes ranging from 13.4M to 14.6M; broker non-votes 5.5M across all director proposals.
Ratification of Crowe LLP as independent auditor approved with 19.9M for, 47.6K against, 98.4K abstentions (no broker non-votes).
72.1% of outstanding shares (20.1M) were present or represented at the June 20, 2025 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.